Pharmaceutical Technology, Nov 2, 2007 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Nov 2, 2007
Online Exclusive
The Continuing Story of Nanoparticles
By R. Christian Moreton
A book illustrates the potential for nanoparticulate drug delivery, and how much about them remains to be understood.
Special Report
Programming a Seamless Supply Chain
By Michelle Hoffman
Information technology is the glue that should unify a company while ironically, it enables further fragmentation. Experts talk about the successes and challenges for IT in helping a company function efficiently.
Peer-Reviewed Research
Mixed-Flow Fans Meet Biosafety Level Laboratory Requirements
By Charlie Gans
Mixed-flow impeller systems exhaust laboratory workstation fume hoods, prevent reentrainment into the facility and adjacent facilities, and help companies comply with appropriate pollution-control standards.
Evaluating Mucilage from Aloe Barbadensis Miller as a Pharmaceutical Excipient for Sustained-Release Matrix Tablets
By Girish K. Jani , Dhiren P. Shah , Vineet C. Jain , Manish J. Patel , Disha A. Vithalani
Natural gums and mucilage have been widely explored as pharmaceutical excipients. The goal of this study was to extract mucilage from the leaves of Aloe barbadensis Miller and to study its functionality as an excipient in pharmaceutical sustained-release tablet formulations.
Improving a Pharmaceutical Water System based on a Risk Analysis Approach
By Arturo Toledo Rivero , Nelson Sierra Prado , Anamarys González Alvarez , Danelys Cardoza Lobaina
In this study, fault tree analysis applied to a water pretreatment and purification installation exposed cause-and-effect complex interrelations in possible fault events.
Investing in High-Potency Manufacturing
By Patricia Van Arnum
Market demand for cytotoxic drugs is leading CMOs to expand their API manufacturing and formulation services.
Inside USP
Inside USP: Annual Scientific Meeting Recap
By Roger L. Williams , Darrell R. Abernethy
Representatives from 17 nations sit down to decide upon standards-setting initiatives.
Washington Report
FDA Amendments Act Raises Confidence and Questions
By Jill Wechsler
New FDA act reshapes drug development and marketing to restore public trust in pharmaceutical regulation.
Mixed Message for Contract Manufacturers
By Jim Miller
Candid comments from a Big Pharma executive highlight the complexity of contract manufacturing.
Agent in Place: Statistically Unstable
By Control, a senior compliance officer
Thin are the lines that separate stability, statistics, and chaos.
The Excipient Information Package, A Win-Win Solution
By David Klug , Ann Van Meter , Laura Horne
The EIP process addresses the problems encountered with numerous questionnaires when qualifying excipient manufacturers.
From The Editor
What Good is Winning a Prize if No One Cares?
By Michelle Hoffman
Thanks to the media, Nobel Laureates are underrated, undervalued, and simply uncool.
This Time Around
Whom Can Patients Rely On?
By Angie Drakulich
As the mother of a 15-month-old, I was quite shaken last month to hear about over-the-counter cold medicines for children under age 2 being pulled off the shelves. Glued to the news, I wondered if the decongestant I had given my daughter when she was sick would have any negative impact on her long-term health.
In the Field
In the Field
The US Food and Drug Administration launched a new program on Oct. 4 to increase the number and variety of generic drugs available to the public, beginning in fiscal year 2008. The Generic Initiative for Value and Efficiency (GIVE) will use existing resources to help the agency "modernize and streamline the generic drug approval process," according to FDA.
In the Spotlight
In the Spotlight
Editors' Picks of Pharmaceutical Science & Technology Innovations
Pharma Capsules
Pharma Capsules
News and Views


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here